Kashyap Patel, MD, discusses the need for provider education on biosimilars.
Transcript:
Basically, we need to educate our colleagues about the science of biosimilars: how they’re developed, how they’re equal, and how the FDA has put in very rigorous standards for evaluating the safety, efficacy, and similarity of the biosimilar molecule to the originator molecule.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.